RCM
BIO icon

Rivermont Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rivermont Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,625
Closed -$7.03M – 24
2023
Q3 		$7.03M Sell
19,625
-1,019
-5% -$393K 3.15% 18
2023
Q2 		$7.83M Sell
20,644
-7,515
-27% -$3.06M 3.61% 15
2023
Q1 		$13.5M Buy
28,159
+4,295
+18% +$2.01M 7.42% 3
2022
Q4 		$10M Buy
+23,864
New +$9.63M 6.35% 8

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rivermont Capital Management's BIO Position: Q4 2023 in Review

Rivermont Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 19,625 shares — an estimated $7.03M sold.

Rivermont Capital Management first reported a position in BIO in Q4 2022 and held it in 4 quarters. The position peaked at $13.5M in Q1 2023. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Rivermont Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Rivermont Capital Management sold 19,625 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $7.03M.
  • Rivermont Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 4 quarters.
  • Rivermont Capital Management's Bio-Rad Laboratories Class A position peaked at $13.5M in Q1 2023.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Rivermont Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.